Meeting
2018 ASCO Annual Meeting
Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC.
Authors
Sonam Puri
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Sonam Puri , Sandrine Niyongere , Monica Sheila Chatwal , Theresa A. Boyle , Dung-Tsa Chen , David Noyes , Scott Joseph Antonia , Jhanelle Elaine Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03377023
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9112)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9112
Abstract #
TPS9112
Poster Bd #
431a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.
First Author: Sonam Puri
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
First Author: Michael B. Atkins